Cipla faces headwinds but remains resilient with strong product portfolio, robust earnings growth potential, and reasonable ...

Obesity affects approximately 100 million Indian adults and is linked to over 200 health complications, including heart ...

Discover if 2025 salary hikes will meet employee expectations. Experts predict modest increments, but will they be enough to ...

US pharma giants eye India’s obesity crisis with pricey shots, sparking ‘Make in India’ and affordability debates ...

US giant, Eli Lilly launched Mounjaro (tirzepatide) which is a prescription medicine for adults with type 2 diabetes used ...

India's obesity crisis is intensifying, with big pharma companies like Eli Lilly and Novo Nordisk competing to introduce ...

The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...

Siddharth Sedani of Anand Rathi Shares & Stock Brokers recommends buying BEL shares for a short-term target of Rs 305 and a ...

Eli Lilly launches Mounjaro in India addressing diabetes-obesity crisis. Approved by CDSCO yet high costs limit accessibility ...

From Indian states sitting on nearly ₹3 lakh crore of idle cash to How Gujarat’s 'semiconductor man' Sudhir Naik built a $300 ...

Eli Lilly’s Mounjaro has launched in India. Approved by CDSCO, it promises significant weight loss and blood sugar control. However, concerns remain over certain side effects.

Eli Lilly & Co. (NYSE: LLY) shares are trading higher Thursday after the company launched its weight-loss drug Mounjaro in ...